0000897069-16-000764.txt : 20160315
0000897069-16-000764.hdr.sgml : 20160315
20160315142302
ACCESSION NUMBER: 0000897069-16-000764
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20160315
DATE AS OF CHANGE: 20160315
EFFECTIVENESS DATE: 20160315
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Romark Global Pharma, LLC
CENTRAL INDEX KEY: 0001666694
IRS NUMBER: 660830393
STATE OF INCORPORATION: PR
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-258025
FILM NUMBER: 161506474
BUSINESS ADDRESS:
STREET 1: B5 TABONUCO STREET, SUITE #216, PMT 317
CITY: GUAYNABO
STATE: PR
ZIP: 00968
BUSINESS PHONE: (787) 919-7987
MAIL ADDRESS:
STREET 1: B5 TABONUCO STREET, SUITE #216, PMT 317
CITY: GUAYNABO
STATE: PR
ZIP: 00968
FORMER COMPANY:
FORMER CONFORMED NAME: Romark Laboratories, LLC
DATE OF NAME CHANGE: 20160211
D/A
1
primary_doc.xml
X0707
D/A
LIVE
0001666694
Romark Global Pharma, LLC
B5 TABONUCO STREET, SUITE #216, PMT 317
GUAYNABO
PR
PUERTO RICO
00968
(787) 919-7987
PUERTO RICO
Romark Laboratories, LLC
Limited Liability Company
true
2014
Jean-Francois
Rossignol, M.D., Ph.D.
3000 Bayport Drive
Suite 200
Tampa
FL
FLORIDA
33607
Executive Officer
Director
Promoter
Marc
S.
Ayers
3000 Bayport Drive
Suite 200
Tampa
FL
FLORIDA
33607
Executive Officer
Director
Promoter
Celine
Rossignol
3000 Bayport Drive
Suite 200
Tampa
FL
FLORIDA
33607
Executive Officer
Brian
Schnieders
3000 Bayport Drive
Suite 200
Tampa
FL
FLORIDA
33607
Executive Officer
W.
Seymour
Holt
3000 Bayport Drive
Suite 200
Tampa
FL
FLORIDA
33607
Director
W.
Andrew
Krusen Jr.
3000 Bayport Drive
Suite 200
Tampa
FL
FLORIDA
33607
Director
Pharmaceuticals
Decline to Disclose
- 06b
true
0000897069-16-000727
2015-10-09
false
true
true
Convertible into Romark SCS Common Units
false
100000
Francisco Jose Rivera
2303039
Pariter Securities, LLC
127836
243 Carretera #2
Guaynabo
PR
PUERTO RICO
00966
PR
PUERTO RICO
false
50000000
10710000
39290000
false
26
1500000
true
0
Commissions paid will be based on 3% of the gross proceeds raised in the offering through the services of the placement agent.
0
false
Romark Global Pharma, LLC
Brian Schnieders
Brian Schnieders
Chief Financial Officer
2016-03-15